{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:08:32Z","timestamp":1793405312946,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40265-025-02217-6","type":"journal-article","created":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T10:34:25Z","timestamp":1754130865000},"page":"1177-1183","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Luvometinib: First Approval"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0121-7645","authenticated-orcid":false,"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,2]]},"reference":[{"key":"2217_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22101551","author":"Y Cheng","year":"2017","unstructured":"Cheng Y, Tian H. Current development status of MEK-inhibitors. Molecules. 2017. https:\/\/doi.org\/10.3390\/molecules22101551.","journal-title":"Molecules"},{"issue":"1","key":"2217_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12916-023-02927-2","volume":"21","author":"X Hu","year":"2023","unstructured":"Hu X, Li W, Zeng K, et al. Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas. BMC Med. 2023;21(1):230.","journal-title":"BMC Med"},{"issue":"Suppl 2","key":"2217_CR3","doi-asserted-by":"publisher","first-page":"S391","DOI":"10.1016\/j.annonc.2023.09.1693","volume":"34","author":"W Li","year":"2023","unstructured":"Li W, Mao Y, Kang Z, et al. A phase II study to explore the efficacy and safety of FCN-159 in recurrent or progressive pediatric low-grade glioma (pLGG) with MAPK pathway-activated [abstract no. 499O]. Ann Oncol. 2023;34(Suppl 2):S391\u20132.","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"2217_CR4","first-page":"929","volume":"8","author":"X-X Cao","year":"2024","unstructured":"Cao X-X, Zhu Q, Cai Z, et al. A multi-center, open-label, single-arm phase II study to evaluate the efficacy and safety of FCN-159 in adults with histiocytic neoplasms [abstract no. P559]. HemaSphere. 2024;8(Suppl 1):929\u201331.","journal-title":"HemaSphere."},{"issue":"3","key":"2217_CR5","first-page":"141","volume":"5","author":"Z Xu","year":"2023","unstructured":"Xu Z, Zhou J, Chen Y, et al. MEK inhibitors for the treatment of extracranial arteriovenous malformations. CJPRS. 2023;5(3):141\u20134.","journal-title":"CJPRS."},{"key":"2217_CR6","unstructured":"Shanghai Fosun Pharmaceutical. Fosun Pharma's self-developed innovative drug luvometinib tablet approved in China [media release]. 29 May 2025. https:\/\/www.fosunpharma.com\/."},{"key":"2217_CR7","doi-asserted-by":"crossref","unstructured":"Lin S, Zhao X, Zhou Z, et al. FCN-159: A novel, potent and selective oral inhibitor of MEK1\/2 for the treatment of solid tumors [abstract no. 1951]. Cancer Res. 2020;80(16 Suppl).","DOI":"10.1158\/1538-7445.AM2020-1951"},{"key":"2217_CR8","volume-title":"Luvometinib: Chinese prescribing information","author":"Shanghai Fosun Pharmaceutical","year":"2025","unstructured":"Shanghai Fosun Pharmaceutical. Luvometinib: Chinese prescribing information. Shanghai: Shanghai Fosun Pharmaceutical; 2025."},{"key":"2217_CR9","unstructured":"National Medical Products Administration. The State Food and Drug Administration approved the marketing of luvometinib tablets [media release]. 29 May 2025. https:\/\/www.nmpa.gov.cn\/."},{"issue":"3","key":"2217_CR10","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1007\/s12325-022-02375-z","volume":"40","author":"J Li","year":"2023","unstructured":"Li J, Tan Y, Li K, et al. Effect of food (low and high fat) on pharmacokinetics of FCN-159, a selective MEK inhibitor, in healthy Chinese males. Adv Ther. 2023;40(3):1074\u201386.","journal-title":"Adv Ther"},{"key":"2217_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejca.2022.08.005","volume":"175","author":"L Mao","year":"2022","unstructured":"Mao L, Guo J, Zhu L, et al. A first-in-human, phase 1a dose-escalation study of the selective MEK1\/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma. Eur J Cancer. 2022;175:125\u201335.","journal-title":"Eur J Cancer"},{"key":"2217_CR12","doi-asserted-by":"crossref","unstructured":"Gu J, Mao L, Guo J, et al. FCN-159, a MEK1\/2 inhibitor, in patients with advanced melanoma harboring NRAS or NF1mutations: a phase 1B dose-expansion study [abstract no. 3095]. J Clin Oncol. 2024;42(16 Suppl).","DOI":"10.1200\/JCO.2024.42.16_suppl.3095"},{"key":"2217_CR13","unstructured":"Zhang R, Liu R, Yu J, et al. The efficacy and safety of luvometinib (FCN-159) in pediatric patients with refractory\/relapsed Langerhans cell histiocytosis: a multi-center, open-label, single-arm phase II study [abstract no. PF502]. In: EHA 2025. 2025."},{"key":"2217_CR14","doi-asserted-by":"crossref","unstructured":"Wang J, Li W, Zeng K, et al. Updated data of efficacy and safety of luvometinib (FCN-159) in pediatric participants with neurofibromatosis type 1 from a multi-center, open-label, single-arm phase 2 study [abstract no. 10044]. J Clin Oncol. 2025;43(16 Suppl).","DOI":"10.1200\/JCO.2025.43.16_suppl.10044"},{"key":"2217_CR15","doi-asserted-by":"crossref","unstructured":"Wang J, Li W, Zeng K, et al. Efficacy and safety of FCN-159, a MEK1\/2 inhibitor in pediatric participants with neurofibromatosis type 1: results from a phase 2 trial [abstract no. 3096]. J Clin Oncol. 2024;42(16 Suppl).","DOI":"10.1200\/JCO.2024.42.16_suppl.3096"},{"key":"2217_CR16","unstructured":"Hu X. Luvometinib (FCN-159) in adult NF1 patients: efficacy and safety outcomes from a multi-center, open-label, single-arm phase II trial [abstract plus poster 4921]. In: NF CONFERENCE. 2025."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02217-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02217-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02217-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:24:47Z","timestamp":1757258687000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02217-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,2]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2217"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02217-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,2]]},"assertion":[{"value":"16 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}